E-ISSN 0976-2833 | ISSN 0975-3583
 

Review Article 


Review Article: Impact of Ivabradine on Cardiovascular Morbidity

Gammone M, Riccioni G, D’Orazio.

Abstract
Heart failure is a complex clinical syndrome with a high incidence all over the world. Although various types of pharmacological
and device therapies are available, the control of increased heart rate (HR) is critical. The bradycardic agent, ivabradine (IVA),
has been displayed to reduce HR by inhibiting the funny current (If). The underlying mechanism states that ivabradine can enter
the hyperpolarization-activated cyclic nucleotide-gated (HCN) channels and bind to the intracellular side, subsequently inhibiting
the If. This phenomenon can prolong the slow spontaneous phase in the diastolic depolarization, and thus, reduce HR. Many
epidemiological studies reported a strong independent association between elevated heart rate and major cardiovascular risk
factors including atherosclerosis, ventricular arrhythmias, and left ventricular dysfunction. The heart rate reduction with IVA
is beneficial in patients with coronary artery disease CAD, chronic stable angina pectoris, and chronic heart failure (CHF), with
acceptable tolerance and safety profile. The pharmacodynamic and pharmacokinetic properties of this drug make it an important
agent in the management of patients with CAD and HF. The aim of this short review is to explore recent results with IVA a new
medication that lowers heart rate by selectively inhibiting the If current, and to describe others future potential applications.

Key words: cardiovascular disease, chronic stable angina, chronic heart failure, heart rate, ivabradine.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Gammone M
Articles by Riccioni G
Articles by D’Orazio
on Google
on Google Scholar
Article Statistics
 Viewed: 1
Downloaded: 0


How to Cite this Article
Pubmed Style

Gammone M, Riccioni G, D'Orazio. Review Article: Impact of Ivabradine on Cardiovascular Morbidity. . 2020; 11(1): 4-8. doi:10.5530/jcdr.2020.11.02


Web Style

Gammone M, Riccioni G, D'Orazio. Review Article: Impact of Ivabradine on Cardiovascular Morbidity. http://www.jcdronline.org//?mno=93798 [Access: March 20, 2020]. doi:10.5530/jcdr.2020.11.02


AMA (American Medical Association) Style

Gammone M, Riccioni G, D'Orazio. Review Article: Impact of Ivabradine on Cardiovascular Morbidity. . 2020; 11(1): 4-8. doi:10.5530/jcdr.2020.11.02



Vancouver/ICMJE Style

Gammone M, Riccioni G, D'Orazio. Review Article: Impact of Ivabradine on Cardiovascular Morbidity. . (2020), [cited March 20, 2020]; 11(1): 4-8. doi:10.5530/jcdr.2020.11.02



Harvard Style

Gammone M, Riccioni G, D'Orazio (2020) Review Article: Impact of Ivabradine on Cardiovascular Morbidity. , 11 (1), 4-8. doi:10.5530/jcdr.2020.11.02



Turabian Style

Gammone M, Riccioni G, D'Orazio. 2020. Review Article: Impact of Ivabradine on Cardiovascular Morbidity. Journal of Cardiovascular Disease Research, 11 (1), 4-8. doi:10.5530/jcdr.2020.11.02



Chicago Style

Gammone M, Riccioni G, D'Orazio. "Review Article: Impact of Ivabradine on Cardiovascular Morbidity." Journal of Cardiovascular Disease Research 11 (2020), 4-8. doi:10.5530/jcdr.2020.11.02



MLA (The Modern Language Association) Style

Gammone M, Riccioni G, D'Orazio. "Review Article: Impact of Ivabradine on Cardiovascular Morbidity." Journal of Cardiovascular Disease Research 11.1 (2020), 4-8. Print. doi:10.5530/jcdr.2020.11.02



APA (American Psychological Association) Style

Gammone M, Riccioni G, D'Orazio (2020) Review Article: Impact of Ivabradine on Cardiovascular Morbidity. Journal of Cardiovascular Disease Research, 11 (1), 4-8. doi:10.5530/jcdr.2020.11.02





Most Viewed Articles
  • Reduced nitrate level in individuals with hypertension and diabetes
    Shiekh Gazalla Ayub, Taha Ayub, Saquib Naveed Khan, Rubiya Dar, Khurshid Iqbal Andrabi
    . 2011; 2(3): 172-176
    » Abstract » doi: 10.4103/0975-3583.85264

  • Association of statin therapy with blood pressure control in hypertensive hypercholesterolemic outpatients in clinical practice
    Manuel Morgado, Sandra Rolo, Ana Filipa Macedo, Miguel Castelo-Branco
    . 2011; 2(1): 44-49
    » Abstract » doi: 10.4103/0975-3583.78596

  • Abdominal obesity, an independent cardiovascular risk factor in Indian subcontinent: A clinico epidemiological evidence summary
    D. S. Prasad, Zubair Kabir , A. K. Dash, B. C. Das
    . 2011; 2(4): 199-205
    » Abstract » doi: 10.4103/0975-3583.89803

  • Utilization of Real-time 3D Transesophageal Echocardiography in an Urban Academic Medical Center
    Lili Zhang, Elaine Y. Lin, Dron Bhandari, Mohan Pamerla, George K. Lui, Cynthia C. Taub
    . 2014; 5(2): 9-14
    » Abstract » doi: 10.5530/jcdr.2014.2.3

  • High prevalence of cardiovascular diseases among other medically compromised conditions in dental patients: A retrospective study
    Sumit Bhateja
    . 2012; 3(2): 113-116
    » Abstract » doi: 10.4103/0975-3583.95364

  • Most Downloaded
  • Sildenafil Improves Right Ventricular Function, Exercise Capacity, and Quality of Life in Patients with Biventricular Dysfunction: Results from a Randomised Study
    Vikas K, Saurabh Mehrotra, Ashwani Sood, Yashpaul Sharma
    . 2020; 11(3): 85-89
    » Abstract » doi: 10.31838/jcdr.2020.11.03.20

  • Evaluation of the RV function in ASD patients pre and post transcatheter occlusion by speckle tracking
    Ghazi Farhan Haji, Venus Abdulwahid Alwan, Sa`ad Hashim Mohammed
    . 2020; 11(1): 24-30
    » Abstract » doi: 10.31838/jcdr.2020.11.01.07

  • Review Article: Impact of Ivabradine on Cardiovascular Morbidity
    Gammone M, Riccioni G, D’Orazio
    . 2020; 11(1): 4-8
    » Abstract » doi: 10.5530/jcdr.2020.11.02

  • Clinical and echocardiogram profile of Cardiomyopathy at tertiary care centre
    Virendra C. Patil, Neeraj Desai,Chetan Galande
    . 2014; 5(1): 34-43
    » Abstract » doi: 10.5530/jcdr.2014.1.6

  • Vascular Endothelial Growth Factor and its Soluble Receptor-1 as Surrogate Markers for Subjects with High-risk of Cardiovascular Disease
    Vipa Boonkitticharoen, Chanika Sritara, Prin Vathesatogkit, Supakajee Saengruang-Orn,Wipa Ratanachaiwong, Piyamitr Sritara
    . 2014; 5(2): 35-42
    » Abstract » doi: 10.5530/jcdr.2014.2.8

  • Most Cited Articles